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In this work, overshoot and undershoot effects associated with step-and-shoot IMRT 
(SSIMRT) delivery on a Varian Clinac 21iX are investigated, and their impact 
on patient-specific QA point dose measurements and treatment plan delivery are 
evaluated. Pinnacle3 SSIMRT plans consisting of 5, 10, and 15 identical 5 × 5 cm2 
MLC defined segments and MU/segment values of 5 MU, 10 MU, and 20 MU were 
utilized and delivered at 600/300 MU/min. Independent of the number of segments 
the overshoot and undershoot at 600 MU/min were approximately ± 10%, ± 5%, and 
± 2.5% for 5 MU/segment, 10 MU/segment, and 20 MU/segment, respectively. At 
300 MU/min, each of these values is approximately halved. Interfractional variation 
of these effects (10 fractions), as well as dosimetric variations for intermediate seg-
ments, are reduced at the lower dose rate. QA point-dose measurements for a sample 
(n = 29) of head and neck SSIMRT beams were  on average 2.9% (600 MU/min) 
and 1.7% (300 MU/min) higher than Pinnacle3 planned doses. In comparison for 
prostate beams (n = 46), measured point doses were 0.8% (600 MU/min) and 0.4% 
(300 MU/min) higher. The reduction in planned-measured point-dose discrepancies 
at 300 MU/min can be attributed in part to the inclusion of the first segment (over-
shoot) in the admixture of segments that deliver measured dose. Pinnacle3 plans 
for 10/9 head and neck/prostate treatments were adjusted by ± 0.5 MU to include 
the effects of overshoot and undershoot at 600 MU/min. Comparing original and 
adjusted plans for each site indicated that the original plan was preferred in 70% 
and 89% of head and neck and prostate cases, respectively. The disparity between 
planned and delivered treatment that this suggests can potentially be mitigated by 
treating SSIMRT at a dose rate below 600 MU/min.
PACS number(s): 87.55.Qr, 87.56.bd, 87.56.N-
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I. INTRODUCTION
In step-and-shoot IMRT using the 120-leaf MLC system on a Varian Clinac 21iX machine 
(Varian Medical Systems, Palo Alto, CA)  the correspondence of planned and delivered dose/
segment is influenced by factors such as leaf positional accuracy, dose rate stability during the 
“shoot” phase, and beamlet on/off control.(1) As far as the latter is concerned, this is limited 
by the frequency (~ 13–20 Hz) with which the MLC controller receives information about the 
delivered MU.(2) This results in a temporal overshoot ~ 50–80 ms(3) and associated overdose 
for the first segment which is ~ 0.5 MU for 600 MU/min.(4) The linac dose monitoring system 
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tracks the cumulative MU for a given beam and initiates beam termination when the planned 
MU is delivered.(5) Consequently the overshoot, coupled with less significant MU discrepancies 
for intermediate segments,(4) causes the last beamlet to be interrupted before the planned MU 
is delivered, the so-called undershoot effect. The significance of these effects increases with 
decreasing MU/segment and decreases with decreasing dose rate.(3) For a given dose rate, the 
magnitude of the overdose and underdose are approximately the same. However, the extent to 
which they negate in beam integral delivered dose is dependent on the overlap of these segments.
At our institution, Clinac 21iX linacs are used to deliver SSIMRT for head and neck and pros-
tate cancer using 600 MU/min. Treatment plans derived using Pinnacle3 v 9.8 (Philips Medical 
Systems, Fitchburg, WI) invariably feature multiple ~ 5 MU segments for which overshoot 
and undershoot effects equate to ~ ± 10% dose delivery discrepancies.(4) For that reason, an 
investigation of SSIMRT segment delivered dose inaccuracies and their interfractional variation 
was undertaken. The dose rate dependence of these effects was evaluated using dose rates of 
600 MU/min (default value at our facility) and 300 MU/min.
In addition, a detailed investigation of intermediate segment dose variation was performed, 
as this had not been previously reported. 
As is common practice, we compare measured and planned point doses (tolerance ± 3%) for 
patient specific SSIMRT QA. The impact of segmental dose errors on the differences between 
them was evaluated at both dose rates as this had not been investigated in previous studies.
Finally, two oncologists reviewed treatment plans for 9 prostate and 10 head and neck 
treatments, with and without allowance for ± 0.5 MU overshoot and undershoot effect. This 
extended the work of Kuperman and Lam(4) and demonstrated how Pinnacle3 v 9.8 can be used 
to clinically evaluate the significance of these effects.
 
II. MATERIALS AND METHODS
A.  Overshoot and undershoot effect
Using Pinnacle3 v 9.8, 6 MV SSIMRT beams consisting of 5, 10, and 15 identical segments were 
configured with doses of 5 MU, 10 MU, and 20 MU per segment. Each segment consisted of a 
5 × 5 cm2 MLC defined aperture and a 6 × 6 cm2 jaw opening with both centered on the CAX. 
Intersegment beam hold-off was achieved by moving an out-of-field leaf pair,(4) the duration 
of this maneuver being sufficient to completely collect charge arising from individual segment 
exposures. Segmental dosimetric measurements were achieved using a 0.6 cm3 Farmer-type 
chamber (NE2571) centered on the CAX, 100 SSD, at a depth of 5 cm in plastic water, and a 
UNIDOSwebline electrometer (PTW, Freiburg, Germany) in signal controlled auto-start mode.
Each SSIMRT beam was delivered 10 times to evaluate interfraction dose variations for 
each segment of a particular beam, and an average chamber reading for each segment was 
calculated. Control segments identical to a single segment of the SSIMRT beams were used 
to deliver 5 MU, 10 MU, and 20 MU prior to the relevant step-and-shoot sequence. Average 
control segment readings for each MU were compared to corresponding segment values and 
percentage deviations between such readings were used to quantify overshoot and undershoot 
effects, as well as MU discrepancies for intermediate segments. All measurements were per-
formed at dose rates of 600 MU/min and 300 MU/min.
B.  Patient-specific QA — point doses
At our institution, point-dose measurements are performed as a part of patient-specific SSIMRT 
QA.(6) A retrospective review was performed to assess differences between measured and 
planned point doses for 246 prostate beams and 418 head and neck beams all delivered using 
600 MU/min. For a selection of plans, point doses were consecutively measured at both 
600 MU/min and 300 MU/min and percentage differences with corresponding planned doses 
were determined. Measurements were performed in plastic water, depth 5.6 cm, using a PTW 
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PinPoint chamber (type 31016) and UNIDOSwebline electrometer according to our patient-
specific SSIMRT QA protocol.
C.  Plan comparison
Pinnacle3 v 9.8 SSIMRT patient treatment plans for 10 head and neck and 9 prostate plans were 
modified by increasing/decreasing the MU of the first segment/last segment by 0.5 MU whilst 
keeping the relative weighting of other segments fixed and the overall beam MU unchanged. 
This MU adjustment corresponds to a representative overdose and underdose of the first and 
last segments at 600 MU/min, respectively.(4) Both adjusted and nonadjusted versions of a given 
plan were de-identified and evaluated by an oncologist to identify the preferred clinical plan. 
 
III. RESULTS 
A.  Overshoot and undershoot effect
Figure 1 shows the percentage deviation of a given segment average reading from the correspond-
ing control segment (± 1 SD) for a 10 segment SSIMRT beam with a segment dose of 5 MU 
and dose rates of 600 MU/min and 300 MU/min. Overshoot and undershoot effects are clearly 
evident and the magnitude of each is approximately ± 10%. Table 1 summarizes the overshoot 
and undershoot for all combinations of MU and segment number investigated. It is evident that 
Fig. 1. Average percentage differences from control segment for 5 MU/segment.
Table 1. Average percentage differences (± 1 SD) from control segment for the overshoot and undershoot segmentsa.
 Segments
 5 10 20 
 Dose Overshoot Undershoot Overshoot Undershoot Overshoot Undershoot
 (MU) (%) (%) (%) (%) (%) (%)
 5 9.2±2.6 13.9±2.1 11.3±4.1 12.0±2.8 11.5±4.0 12.6±3.3
  (6.2±1.7) (6.1±1.6) (4.9±1.4) (5.8±1.9) (5.1±1.2) (6.1±1.1)
 10 5.8±1.3 7.1±1.2 6.5±1.0 6.5±1.5 5.4±1.1 6.1±1.1
  (3.3±0.3) (2.5±0.7) (3.5±0.6) (2.8±0.8) (3.0±0.6) (2.6±0.8)
 20 2.7±0.7 3.2±0.7 3.2±0.5 3.2±0.5 2.6±0.7 3.1±0.9
  (1.7±0.2) (1.4±0.3) (1.7±0.3) (1.1±0.5) (1.5±0.4) (1.2±0.4)
a Values for 300 MU/min are shown in brackets.
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the magnitude of these effects is essentially independent of the number of segments (ANOVA 
p > 0.05). Comparison of these effects for 600 MU/min and 300 MU/min indicates that both are 
reduced by a factor of two at the lower dose rate, which is consistent with previously reported 
work.(3,4) For a given number of segments and dose rate, the overshoot and undershoot for 5, 
10, and 20 MU are approximately in the ratio 1:0.5:0.25 (Table 1). Interfractional variations 
of overshoot and undershoot at both dose rates are shown in Fig. 2 for a 10-segment 5 MU/
segment SSIMRT beam. At the higher dose rate, greater deviations from the mean overshoot 
and undershoot are observed (Table 1). 
Intermediate segments exhibit smaller average percentage differences (Fig. 1) from their 
respective reference values, as has been reported(4) and do not exhibit the same ~ 2:1 ratio as the 
overshoot and undershoot effects with decreasing dose rate. For a 10-segment SSIMRT beam, 
Fig. 3 shows a comparison of the interfraction variations measured for segment 8 at both dose 
rates. In general, as can be seen from Table 2, both the standard deviation and the percentage 
difference range are greater at 600 MU/min.
Fig. 2. Interfractional variation of overshoot and undershoot effects for 300 and 600 MU/min for segment 1 (S1) and 
segment 10 (S10).
Fig. 3. Example of intermediate segment interfractional variation for 300 and 600 MU/min.
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B.  Patient-specific QA — point doses 
The review of quality assurance measurements, as discussed above, demonstrated that measured 
dose was systematically larger than planned dose in 76% of head and neck fields and in 71% 
of prostate fields. 
For a sample (n = 29) of the head and neck fields, measured point dose were on average  2.9% 
and 1.7% higher at 600 MU/min and 300 MU/min, respectively, with a maximum absolute dif-
ference between corresponding measured point doses at both dose rates of 4%. In comparison, 
corresponding differences of 0.8% and 0.4% were observed for prostate fields (n = 46) with 
a maximum absolute difference of 2.4% between measured point doses at these dose rates.
C.  Plan comparison
Head and neck plans were discriminated on the basis of the conformity index formalism proposed 
by Paddick(7) and PTV coverage. In 70% of cases the original plan was preferred on the basis 
of greater conformity index. Figure 4 shows a comparative DVH for one such plan, and it is 
noted that the PRV SC 5 mm maximum dose for the original/adjusted plan is 44.8 Gy/45.8 Gy. 
The relevant local dose constraint is 45 Gy and, in as much as the adjusted plan reflects treat-
ment delivery, suggests that this constraint may not be achieved. Figure 5 shows the absolute 
difference of PTV V95% between adjusted and nonadjusted plans. When the adjusted plan was 
preferred (plans 2, 4, and 10), it was on the basis of greater PTV coverage, albeit the conformity 
index was slightly reduced.
Table 2. Standard deviation and range of percentage differences from segment reference values for intermediate 
segments.
 Dose rate
 (MU/min) 5 MU/Segment 10 MU/Segment 20 MU/Segment
 600 SD: 3.3% SD: 1.5% SD: 0.8%
  Range: -11.1%–3.1% Range: -5.4%–1.7% Range: -2.6%–0.7%
 300 SD: 1.9% SD: 1.1% SD:  0.6%
  Range: -5.3%–2.4%  Range: -2.6%–0.1% Range: -1.1%–0.1%
Fig. 4. Example DVH for a head and neck treatment plan with the adjusted plan incorporating an overshoot/undershoot 
effect.
119  Baines et al.: Clinical implications of MLC overshoot 119
Journal of Applied Clinical Medical Physics, Vol. 17, No. 4, 2016
Prostate plans could not be differentiated using the same definition of conformity index for 
PTV60/78 and PTV54/66. Instead, preference was determined by dose to the rectum and blad-
der and, in 89% of cases, the original plan was selected (for one plan the adjusted/nonadjusted 
plans were equivocal). Rectal dose constraints were V40 < 35% and V65 < 17% for PTV60/78 
and V40 < 55% and V65 <35% for PTV54/66. Similarly bladder dose constraints were V40 < 
50%, V65 < 25% and maximum dose ≤ 81.9 Gy for PTV60/78 and V40 < 70 %, V65 < 60% 
and maximum dose ≤ 69.3 Gy for PTV54/66. For all adjusted plans, rectal and bladder doses 
were higher. Table 3 shows average absolute differences for each dose constraint. Figure 6 
shows a representative comparative DVH showing higher dose to the PTV, bladder, and rectum 
for the adjusted plan.
 
Fig. 5. PTV V95% absolute difference between adjusted and nonadjusted H&N plans.
Table 3. Absolute average difference of OAR dose constraints between adjusted and nonadjusted prostate plans.
  V40 V65 Max Dose
 OAR (%) (%) (Gy)
 Rectum 0.6 0.9 -
 Bladder 0.3 0.7 0.4
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IV. DISCUSSION
A.  Overshoot and undershoot effect
With a Clinac 21iX linac there is a temporal mismatch, Δti, between planned and actual beam 
on time for the ith segment of a step-and-shoot IMRT beam.(3) The average magnitude of this 
mismatch for the first and last segments (~ 50–80 ms) is significantly greater than that for 
intermediate segments, giving rise to the so-called overshoot and undershoot effects. In the 
absence of other factors, the delivered dose discrepancy for the ith segment, ΔDi is given by
 ΔDi = Δti × R (1)
where R is the dose rate.(2) As the dose per segment, Di, is reduced the significance of ΔDi 
increases for a given value of R, as is reported by Kuperman and Lam(4) and observed in this 
work. From Table 1 it is evident that, independent of the number of segments, the average over-
shoot effect is approximately 10%, 5%, and 2.5% for MU/segment values 5 MU, 10 MU, and 
20 MU, respectively. With the dose rate reduced to 300 MU/min, the overshoot for each MU is 
halved. For intermediate segments, a delayed beam-on coupled with a delayed beam-off give 
rise to Δti values that are generally less than those of the first and last segments.
(2) For the last 
segment, beam delivery is terminated when the linac monitor identifies that the cumulative MU 
for the SSIMRT beam has been achieved. Dose reduction for the last segment is in large part 
due to the overshoot of the first segment and is the reason why the overshoot and undershoot 
effects are of similar magnitude. This is consistent with the observations presented in Table 1 
and reported elsewhere.(2) Interfractional variations of the overshoot and undershoot effects are 
dependent on dose rate (Fig. 2) which is also the case for intermediate segment doses (Fig. 3 
and Table 2). Such observations suggest that machine delivery limitations can be mitigated by 
opting for a reduced dose rate at treatment delivery.
Fig. 6. Example DVH for a prostate treatment plan with the adjusted plan incorporating an overshoot/undershoot effect.
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B.  Patient-specific QA — point doses 
Figure 7 shows beam’s eye view (BEV) examples for the first and last segments of head and 
neck and prostate SSIMRT fields obtained using the Pinnacle3 v 9.8 IMRT plan optimization 
algorithm. Clearly the overshoot and undershoot effects of these segments do not negate each 
other. Further, when selecting suitable points for treatment plan QA, it was found in our review 
that invariably the admixture of beamlets delivering dose to the PTW chamber included the 
first but not the last segment. This arises from the open area and weighting attributed to the first 
segment in the Pinnacle3 optimization of control point sequences for each beam. Given this bias 
in selection of calculated/measured point doses, the overshoot effect of the first segment will 
give rise to a dose rate dependent contribution to point dose measurements (Eq. (1)). In addition, 
the discrepancy between measured and calculated point doses is influenced to some extent by 
each ΔDi in the beamlet admixture contributing to measured dose. However, using dose rates 
of 600 MU/min and 300 MU/min, it has been reported here that average planned-measured 
point-dose discrepancies are smaller at the lower rate, albeit that interfraction variations in Δti 
Fig. 7. BEV examples of the first (a) and last segment (b) for a head and neck treatment plan, and the first (c) and last (d) 
segment for a prostate treatment plan.
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impact on measurements at each dose rate for a given point and beam. The average MU for the 
first segment of the prostate and H&N plans investigated is 19 MU and 8 MU, respectively. 
Consequently, the percentage overshoot effect is less for prostate plans and thus the dose rate 
dependence of point-dose discrepancies is less than for H&N plans.
C.  Plan comparison
In principle, the dosimetric discrepancies associated with Δti may be reduced by modifying the 
segment sequences of SSIMRT delivery.(4,5) For example, if the first segment MU is halved 
and a duplicate segment with the same MU is configured as the last segment of the beam, the 
overshoot and undershoot effects will negate each other. In practice, such segment manipula-
tion is not a feature of Pinnacle3 v 9.8. However, it is possible to adjust the MU of the first 
and last segments whilst constraining the weighting of other segments(5) as is reported in this 
work. With an increase/decrease of 0.5 MU for the first/last segments, head and neck-adjusted 
plans, indicative of machine delivery, were inferior to the nonadjusted plans representative of 
an idealized machine performance. This suggests that the correspondence of planned/delivered 
treatment is enhanced at a dose rate of 300 MU/min. Reducing the dose rate doubles segment 
beam on time but, in terms of treatment delivery time that involves intersegment leaf motion 
as well as gantry rotation, the overall treatment time is not significantly extended at the lower 
dose rate. For the sample of H&N treatments investigated, the maximum MU/fraction was 
755 MU, corresponding to increase in treatment of approximately 80 s.
For the prostate plans investigated, clinical evaluation indicates that nonadjusted plans are 
preferred on the basis of reduced dose to the bladder and rectum. This further supports the view 
that, at a reduced dose rate, machine delivery is a better approximation to actual treatment plans.
 
V. CONCLUSIONS
When performing patient-specific QA point dose measurements it has been shown that, for 
the prostate and head and neck plans investigated, greater discrepancies between planned and 
measured dose occur for the latter. These discrepancies are in part attributed to the inclusion 
of the first segment in the admixture of segments contributing to measured dose. However, the 
first SSIMRT segment MU in head and neck plans is significantly less than that for prostate 
plans. Consequently, the percentage overshoot effect is greater for head and neck plan delivery 
and greater planned-measured point dose discrepancies are to be expected. Due to the dose rate 
dependence of the overshoot effect, such discrepancies for head and neck plans decrease more 
than for prostate plans when the dose rate is decreased.
Interfractional variation of intermediate segment doses is also reduced with decreasing dose 
rate. For the 10 fractions sampled, at each dose rate it was observed that for varying segments 
within each fraction the dose discrepancy could intermittently approximate to the overshoot/
undershoot for that dose rate. Overall, the temporal errors associated with segment dose delivery 
in SSIMRT can be mitigated by treatment delivery at the lowest clinically viable dose rate. 
Modifications to the MU of the first and last segments of SSIMRT beams is a means to 
reduce the effects of Δti and improve the consistency of treatment plans and delivered dose, 
albeit such an approach ignores the effects of intermediate segment variations ΔDi. Based on 
the review of adjusted and nonadjusted plans reported in this work, it is evident that preference 
clinically was given in large part to the nonadjusted plans. However, the adjusted plans are 
potentially more indicative of treatment delivery at 600 MU/min. Whilst use of this dose rate 
may optimize treatment delivery time, operating at a lower dose rate, such as 300 MU/min, 
improves planned-delivered dose agreement with acceptable increases in treatment time. Further, 
treatment plans indicating OAR target doses below tolerance levels may in fact be misleading 
when overshoot effects in treatment delivery at 600 MU/min increase doses above these levels.
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